PREQUALIFICATION FEES

WHO Prequalification of In Vitro Diagnostics
© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.


Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.
1. Introduction

WHO Prequalification of In Vitro Diagnostics undertakes a comprehensive assessment of individual in vitro diagnostics (IVDs) through a standardized procedures aimed at determining if the product meets WHO prequalification requirements. In addition, once a product is prequalified, WHO assesses all reportable changes to verify that the product continues to meet WHO prequalification requirements.

This document provides information on the fees associated with WHO prequalification, and the payment process thereof. There are three types of fees associated with WHO prequalification:

- A prequalification assessment fee per product;
- An annual fee per product; and
- A change assessment fee per product.

The abovementioned prequalification assessment, annual and change assessment fees are non-refundable, and cover in part the cost incurred by WHO in connection with the prequalification process.

Manufacturers should note that WHO reserves the right to decide, based on the prequalification assessment and change assessment findings, whether a product meets the applicable WHO requirements to be prequalified and/or whether to accept a change.

Payment of the prequalification assessment, the annual and/or the change assessment fees does not guarantee that the product will be prequalified, or that a prequalified product will maintain its WHO-prequalified status, or that the change will be accepted.

The section “Exemption from fees” provides details of the categories of changes which are exempt from change fees.

2. Intended audience

This document has been prepared to provide manufacturers with detailed information on the fees applicable to WHO prequalification and the payment process thereof.

3. Prequalification assessment fee per product and payment process

The prequalification assessment fee is charged to a manufacturer once its application has been determined as eligible for WHO prequalification assessment.

The prequalification assessment fee will contribute to cover part of the costs associated with product dossier screening and review, performance evaluation commissioned by WHO, manufacturing site(s) inspection, review of labelling and dissemination of prequalification information.
The following fees apply to applications accepted for WHO prequalification assessment:

- For applications undergoing a full prequalification assessment: US$ 5 000 for dossier screening and US$ 12 000 for product assessment, per product; or
- For applications undergoing an abridged prequalification assessment: US$ 8 000 per product.

WHO will issue an invoice to the manufacturer to request payment of the prequalification assessment fee. The prequalification assessment process will not commence unless WHO has first received the full amount of the applicable prequalification assessment fee as well as written evidence of payment thereof. Failure to pay the prequalification assessment fee within the defined timelines will result in cancellation of the application.

Payment of the prequalification assessment fee does not, however, guarantee that the product will be prequalified by WHO.

4. Change assessment fee per product and payment process

WHO will review the change documentation submitted by the manufacturer to determine the type and level of assessment required which, in turn, will determine whether change assessment fees are charged. When applicable, the change assessment fee is US$ 3 000 paid in one instalment.

The change assessment fee will contribute to cover the costs associated with the change assessment and dissemination of the change information.

WHO will issue an invoice to the manufacturer to request payment of the change assessment fee. The change assessment process will not commence unless WHO has first received the full amount of the change assessment fee as well as written evidence of the payment thereof. Failure to pay the change assessment fee within the defined timelines will result in cancellation of the change request application.

Payment of the change assessment fee does not, however, guarantee that the product will be prequalified or the change accepted by WHO.

4.1 Exemption of change assessment fees

Exemption of change assessment fee is applicable in certain cases. WHO does not charge fees for the assessment of administrative changes and for certain abridged reviews; the applicability of the exemption is determined by WHO on a case by case basis, depending on the extent of the required assessment work. The manufacturer will be informed if such exemption is applicable in writing.

---

1 The fee equally applies to performance evaluation options 1 and 2.
2 Only one product can be submitted within an application. This may include several product configurations.
3 Completed WHO document PQDx 119 Change Report Form and supporting documentation.
4 For details on administrative changes refer to WHO document PQDx_121 v2 “Reportable Changes to a WHO Prequalified In Vitro Diagnostic Medical Device”.
5. Annual fee per product and payment process

An annual fee of US$ 4 000 is levied on a yearly basis for each product listed on the WHO list of prequalified in vitro diagnostics.

An invoice for the annual fee will be issued by WHO to the manufacturer on or before 1 October of each year. The annual fee will be applicable to all IVDs that, by 1 September of that year, have been listed on WHO’s list of prequalified in vitro diagnostics for 12 months or more. Payment of the annual fee must be made before 30 November of the calendar year in which the invoice is issued.

Failure to pay the annual fee within the defined timelines will result in suspension of the prequalification status of the prequalified product.

Payment of the annual fee does not, however, guarantee that a prequalified product will not, for other reasons, be removed or suspended from the WHO list of prequalified IVDs.

6. Date of effect

This fees schedule is effective and applies as follows:

(i) the prequalification assessment fee will apply to all applications for WHO prequalification assessment that are received by WHO on and after 1 August 2018;
(ii) the annual fee will apply as of 1 August 2018; and
(iii) the change assessment fee will apply to all applications for change assessment to a prequalified IVD that are received by WHO on and after 1 August 2018.

7. Contact information

Any inquiries regarding WHO Prequalification of IVDs should be addressed to: diagnostics@who.int